×

Lipocine Inc. (Nasdaq: LPCN) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Jan. 16, 2015 (GLOBE NEWSWIRE) --

What:

Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Mahesh Patel, Chairman, President and Chief Executive Officer will ring the Closing Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Tuesday, January 20, 2015 – 3:45 p.m. to 4:00 p.m. ET

Lipocine Inc. Media Contact:
Morgan Brown
(801) 994-7383 ext. 2174
mb@lipocine.com

Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Lipocine Inc. (Nasdaq:LPCN):

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's lead product candidate, LPCN 1021, demonstrated positive top-line efficacy results in Phase 3 testing and is targeted for testosterone replacement therapy. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth, and is currently in Phase 1 testing.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.

-NDAQA-

Source:The NASDAQ OMX Group, Inc.